Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

Kyle LaHucik

Senior Reporter

Kyverna Therapeutics has reshaped its C-suite just seven months after securing one of the splashiest biotech IPOs in recent years as it rode the waves …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO